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1. Introduction 
Intravascular ultrasound is a clinical tool that has been used in a complimentary manner to 
contrast angiography in order to enhance the procedure success rate and patient outcomes. 
Particularly, there are some specific situations where IVUS can be very useful and information 
from IVUS overcome angiography limitations. These situations can be divided into three parts: 
- pre-interventional 
- during intervention 
- post-interventional 
Pre-interventional use of IVUS can help with assessment of hemodynamic significance of 
stenosis (in this place must be emphasized, that IVUS can estimate hemodynamic significance 
only non directly, but with acceptable correlation with fractional flow reserve and nuclear 
stress test), precise anatomic analysis (type of bifurcation, plaque burden in ostial part of side 
branch or left main) and can help with device selection: precise measurement of diameters in 
reference segments for better sizing of balloon or stent, type of lesion preparation such as 
dilatation with cutting balloon or atherectomy devices in bulky lesions, drug eluting stent for 
lesions with high probability of small in stent area achievement.    
IVUS can be used during intervention for assessment of lesion preparation (proper position 
of wire; especially it’s relation to stent struts, effect of predilatation, assessment of side 
branch ostium) for guiding in more complicated intervention (left main stenting, navigation 
of wires during PCI of chronic total occlusion, trifurcation PCI). 
Post-interventional use of IVUS can answer questions about result adequacy (stent 
expansion, stent apposition), angiographic filling defects  (“hazy  lesions”) after PCI (edge 
dissection, thrombus formation, inadequate stent expansion, prominent calcification) and 
diagnosis of complications (dissection, geographic mismatch, plaque protrusion inside the 
stent, inadequate stent expansion or apposition). IVUS can in most cases also reveal  the 
reasons behind development of complications after PCI such is in stent thrombosis (mainly 
inadequate stent expansion or edge troubles such as dissection, or uncovered lesion) or 
unexpected early in stent restenosis (inadequate stent expansion).   
IVUS is a mandatory tool in the cardiac catheterization laboratory today. Like all medical 
equipments it should be used by an experienced investigator for better understanding of 
PCI mechanisms, prevention and solution of complications. Nowadays it is possible to use 
many semi-automatic softwares for border detection, but all of them must be corrected 
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manually to avoid serious mistakes and misunderstanding. The best way how to do that is 
just routine use of IVUS. 
1.1 Limitation of angiography  
Angiography is a gold standard for assessment of atherosclerotic impairment of coronary 
arteries and for guiding of coronary intervention. On the other hand it has many limitations. 
Widely accepted decision making point for diagnosis of flow-limiting lesion is lumen 
diameter less than 50% of the reference segment.  However, it has been proven that there is 
no correlation between angiography assessment and functional measurement by fractional 
flow reserve (FFR) in intermediate lesions between 40-70%1.  
Based on autopsy studies we know, that atherosclerosis is more often diffuse than focal 
process affecting coronary arteries. These findings are in good correlation with intravascular 
ultrasound. The reference segment, which is angiographically normal often contains 
atherosclerotic plaques visible on IVUS. From this point of view we are comparing less 
affected segments with more affected ones during angiography and thus underestimate 
stenosis significance2,3. Other challenging issues are assessment of ostial lesions and 
bifurcations. 
2. Quantitative lesion assessment  
2.1 Technique  
The most important parameter for quantitative lesion assessment is minimal lumen area 
(MLA), which has the best correlation with presence of ischemia (see below).Common 
misunderstanding comes from the assessment of relative severity of stenosis in 
percentage of “normal” reference diameter. Angiographic stenosis assessment is based on 
comparison of lumen diameter in reference segment and lumen diameter in the lesion. 
The most corresponding IVUS parameter is lumen area stenosis (LAS), which is calculated 
as minimal lumen area in reference segment – minimal lumen area in lesion / minimal 
lumen are in reference segment. More frequently used description of stenosis is plaque 
burden (PB), computed as external elastic membrane area – lumen area / external elastic 
membrane area4. We must interrogate each frame and look for the smallest lumen area, 
use routinely nitrates before IVUS probe insertion for avoiding spasms. In case of 
uncertainty in lumen measurement, especially in present of soft plaque it is recommended 
to flush guiding catheter by saline for clearing of picture. Using of automatic pullback 
devices is not necessary for quantitative lesion assessment, but allows us to perform 
longitudinal diameters or volumetric analysis. Manual pullback is better for analysis of a 
precise part of plaque, where we can stop IVUS probe to obtain more frames from the 
region of interest. For imaging of aorto-ostial lesions it is necessary to retract the guiding 
catheter back into the aorta and verify that the path of the IVUS probe is still coaxial with 
the ostium of the vessel5.   
2.2 Indication for coronary intervention 
The main indication for coronary intervention is lesion producing myocardial ischemia, 
which can be detect either non-invasively by stress myocardial perfusion imaging (SPECT) 
or invasively by measurement of pressure gradient across stenosis (fraction flow reserve, 
FFR). IVUS measurement correlates with both of them (table one).  
www.intechopen.com
 IVUS Guided PCI 
 
109 
Author Description Methods No of 
patients
Results 
Briguori6 angiographic stenosis 
40-70% 
IVUS vs. 
FFR 
43 FFR < 0.75 correlates with:
-
 MLA ≤ 4 mm2 
- MLD ≤ 1.8 mm 
- PB > 70% 
- Lesion length > 10 mm 
Abizaid7 patients indicated for 
PCI 
IVUS vs. 
CFR 
73 CFR ≥ 2 correlates with: 
-
 MLA ≥ 4 mm2 
- MLD ≥ 2 mm
Nishioka8 consecutive IVUS 
examinations 
IVUS vs. 
myocardial 
SPECT  
79 Positive  scan correlates with: 
- MLA ≤ 4 mm2 
- PB > 73% 
- LAS >59%
Takagi9 consecutive IVUS 
examinations  
IVUS vs. 
FFR 
42 FFR <0.75 correlates with:
-
 MLA ≤ 3 mm2 
- LAS > 60%
Lee10 vessels smaller than 3 
mm 
IVUS vs. 
FFR 
94 FFR < 0.75 correlates with:
- MLA ≤ 2.0 mm2 
- PB ≥ 80% 
- Lesion lenght ≥ 20 mm    
Abizaid11 IVUS deferred PCI IVUS 300 Safe deferral of PCI correlates with: 
- MLA ≥ 4 mm2  
-
 MLD ≥ 2 mm 
Jasti12 ambiguous left main 
stenosis 
IVUS vs. 
FFR 
55 FFR < 0.75 correlates with:
-
 MLA ≤ 5.9 mm2 
- MLD ≤ 2.8 mm
Abizaid13 patients with 
borderline left main 
stenosis 
IVUS 122 MACE predictor :
-
 MLD ≤ 3.0 mm 
Kang 14 Consecutive patients IVUS vs. 
FFR 
201 FFR <0.80 correlates with:
-
 MLA 2.4 mm2  
- PB ≥79% 
Ben Dor15  patients with 
intermediate lesion 
during QCA   
IVUS vs. 
FFR 
84 FFR < 0.8 correlates with:  
- MLA 2.4 mm2 mm  for vessels  
2.5-3.0 mm 
- MLA 2.7 mm2 for vessels 3.0-3.5 mm 
- MLA 3.6 mm2 for vessels >3.5 mm 
Ahn16 consecutive patients 
with SPECT and 
IVUS
IVUS vs. 
SPECT 
150 Positive scan correlates with: 
- MLA 2.1 mm2 
PROSPECT17 clinical follow-up 
after ACS 
IVUS  and 
MACE 
700 Predictors for MACE:
- PB > 70% 
- MLA < 4 mm2 
- TCFA 
Abbreviations: CFR - coronary flow reserve, MACE – major cardiac adverse event, MLA – minimal 
lumen area, MLD – minimal lumen diameter, PB - plaque burden, PCI- percutaneous coronary 
interventions, QCA – quantitative coronary angiography, SPECT – single photon emission computed 
tomography, TCFA thin cap fibroatheroma   
Table 1. Studies with IVUS evaluation of hemodynamic significance  
www.intechopen.com
 Intravascular Ultrasound 
 
110 
Based on older  studies  the following recommendations for IVUS detection of significant 
stenosis were established: 
Main epicardial artery: 
- MLA < 4 mm2 
- MLD < 2 mm 
Left main:  
- MLA < 6 mm2 
- MLD 3 mm  
However, recently published studies do not support these cut-off values. Instead of clear 
cut-off points there are number of different recommended values, which do not seem to be 
useful for routine practice. Based on these findings   we must conclude that IVUS is not 
suitable for assessment of haemodynamic significance of intermediate lesions. IVUS can be 
only used for exclusion of haemodynamicly significant lesion with MLA more than  4 mm2 
for main epicardial arteries and more than 6 mm2 for left main. The haemodynamic 
significance of each lesion is caused not only by lumen area, but also by amount of viable  
myocardium  supplied by this vessel and by presence or absence of collaterales. These facts 
simply cannot be examined solely by a morphologic modality like IVUS.   On the other hand 
the PROSPECT trial17 with clinical endpoints  confirmed, that large plaque compromising 
lumen to 4 mm2 and less, especially together with higher content of necrotic tissue is a risk 
factor for future events. These issues will be matter of further studies. 
There are no data about IVUS criteria for hemodynamic significance in saphenous vein 
graft, but it is recommend to use a cut-off point MLA 4 mm2 for graft supplying one 
coronary artery and MLA 6 mm2 for graft supplying two arteries. 
The precise assessment of hemodynamic significance is a crucial point, because the rate of 
ischemic events is 5-10% / year in significant lesion and less than 1%/ year in non-ischemic 
lesion. Performing PCI in non-ischemic lesion increase risk of event to 2-3% / year18 and 
furthermore increases risk of periprocedural ischemia or myocardial necrosis during PCI.  
Very old IVUS-skeptic sentence “If you want to stent, do IVUS” was quite recently 
supported by the work of Nam et al.19. Authors randomized 167 patients with intermediate 
coronary lesion between FFR guided (cut-off for PCI was FFR <0.8) and IVUS guided (cut-
off MLA< 4.0 mm2) coronary intervention. PCI was performed in 33.7% lesion in FFR arm 
and in 91.5% in IVUS arm. This difference was highly statisticaly significant (p<0.001). On 
the other hand we ourselves have a different experience with IVUS assessment in borderline 
lesions. We estimate that we are performing PCI in 40-50% of borderline lesions based on 
IVUS criteria, which is closer to FRR guided arm in this study. The finding of 91.5% 
frequency of MLA < 4 mm2 in lesion between 40-70% is in our eyes unrealistic.  
2.3 Assessment of left main (LM) 
Left main stenosis is a very important predictor for future cardiac events20. Angiographic 
assessment of LM is often complicated for overlapping branches and short or no reference 
segment and can lead to inappropriate estimates of lesion severity21. IVUS is more sensitive 
for left main atherosclerosis than angiography22. Suter et al.23 found that in half of the 
patients with an inconclusive angiogram IVUS detects a significant stenosis.  There is no 
difference for left main assessment during pullback from left anterior descending artery 
(LAD) or left circumflex artery (LCX)24. On the other hand for accurate assessment of ostial 
part of LAD and LCX is  necessary to perform two pullbacks from both daughter vessels, 
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because oblique view can overestimates lumen area25. The main target in left main 
bifurcation (like in other bifurcation) is to make a decision between one or two stent 
strategy. Pullback from just one daughter artery can answer the question whether the 
ostium of second branch is affected or not. For a more precise evaluation of minimal lumen 
area it is necessary to perform pullback from both daughter branches. 
The precise coaxial position of guiding catheter is important for measurement or ostial left 
main stenosis, other than coaxial position of guiding catheter overestimates the lumen area. 
This type of inappropriate measurement can be detected by elliptical instead of spherical 
shape of ostial left main.   
The ostium of LM can be influenced not only by atherosclerosis but also by external 
compression between enlarged pulmonary artery and aorta. This compression occur during 
systolic phase and lumen is enlarged during diastolic phase (figure 1,2). This finding can be 
seen in patients with severe pulmonary artery hypertension 
According to our experience we recommend to perform all PCI´s of LM with IVUS 
guidance. This is supported by results of MAIN-COMPARE registry, where IVUS guidance 
of left main PCI was superior to angiographic guidance26. 
 
 
Fig. 1. External compression of left main during systolic phase of cardiac cycle. “Kmen ACS” 
means left main coronary artery. 
 
Fig. 2. No evidence of left main compression during diastolic phase of cardiac cycle. 
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3. Lesion morphology 
3.1 IVUS in lesion with angiographic filling defect “hazy lesions” 
The main finding in so called hazy lesions is a defect in the contrast filling of coronary 
artery. The reasons for this include:  
- eccentric calcification (figure 3)  
- significant stenosis  
- dissection (figure 4)  
- thrombosis (figure 5)  
- plaque rupture (figure 6) 
- “flow phenomenon” (inadequate filling of big arteries during dye injection).  
Thrombus is the most dangerous cause and many hazy lesions are treated like thrombus-
containing lesions with administration of IIbIIIa glycoprotein inhibitors, use of embolic 
protection devices or covered stents. However, real presence of intracoronary thrombosis is 
50-60% of all hazy lesions27. Sensitivity of IVUS for thrombus is low (about 50%), so from 
IVUS picture we simply cannot rule out the presence of thrombus (the highest sensitivity for 
thrombus has optical coherence tomography), but IVUS can confirm other causes and 
mainly causes which are not indicated fore PCI. This strategy decreases frequency of PCI in 
hazy lesions to 15-20%28-30  
 
 
Fig. 3. Eccentric calcification. 
 
 
Fig. 4. Dissection with visible tear (arrow) and small thrombus (in circle). 
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Fig. 5. Huge thrombus located on very small plaque causing acute coronary syndrome. 
Left side is cross sectional view, right side is longitudinal view (thrombus is located in the 
circle). 
 
 
Fig. 6. Plague rupture with visible cavity after embolization of plaque mass. Patient with 
acute myocardial infarction. 
3.2 Aneurysms 
True aneurysm is defined as both an external elastic membrane (EEM) and lumen area 50% 
larger than the proximal reference segment with intact three layers of vessel wall (figure 7). 
Lesions which seem to be the aneurysms from angiographic assessment are an true aneurysm 
in 37% of such findings. The rest are normal segments adjacent to plaque (53%), complex 
atherosclerotic plaque (16%) and pseudoaneurysm (4%)31. Coronary pseudoaneurysm is due 
to rupture of vessel wall and in IVUS picture the three layers of vessel are not present, the 
shape of pseudoaneurysm is often irregular. From a practical point of view, pseudoaneurysms 
are seen only after coronary interventions causing trauma of vessel wall. 
www.intechopen.com
 Intravascular Ultrasound 
 
114 
 
Fig. 7. Stent located in coronary aneurysm. 
3.3 True versus false lumen  
False lumen is created by dissection, either spontaneous or iatrogenic during coronary 
intervention (wire insertion or after balloon/stent dilatation). Dissections are treated by 
stent implantation and a flow non limiting dissection can be let to spontaneous healing. 
Stent insertion to the true lumen is a crucial point for proper treatment of dissection. True 
lumen can be identified by three-layered appearance and by origin of side branches. False 
lumen contains more echogenic blood flow5 (figure 8).  
 
 
Fig. 8. Dissection with IVUS probe located in the false lumen with staying blood. 
4. Balloon angioplasty  
4.1 The mechanism of balloon PCI 
The main mechanism of lumen enlargement during balloon dilatation is a plaque rupture, 
which enables lumen dilatation32. This finding was also confirmed by IVUS during in vivo 
studies, mainly in eccentric plaques (which are mainly present in coronary arteries). 
Another mechanism of lumen enlargement during balloon angioplasty is plaque 
compression and plaque redistribution, which are the main mechanism in concentric 
plaques33.  
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4.2 IVUS guided plain balloon PCI 
Several studies have been conducted in this field. Their results are summarized in table 2. 
 
study target restenosis MACE  comments 
CLOUT34 
102 pts. 
using larger balloon 
than angiographicly 
measured vessel 
diameter 
not declared  1.9%* 
  
plaques compensated by 
positive remodeling allow 
use of aggressive dilatation 
without  risk of significant 
dissections   
Haase35 
144 pts. 
IVUS guided 
balloon dilatation 
21%+ 12+%  use of larger balloon than 
angiographic lumen 
diameter is safe and with 
low risk for restenosis  
Schroeder36  
252 pts. 
IVUS guided 
balloon dilatation  
19%+ 14+% small dissection are not 
flow limiting    
IVUS decreases number of 
implanted stents  
low restenosis comparable 
with BMS 
Abizaid37 
284 pts. 
IVUS guided 
balloon dilatation 
and stent only in 
case of 
unsatisfactory result 
8%+- PCI  
16% - stent  
8%+ - PCI  
11%- stent  
„stent like“ effect after 
IVUS guided balloon 
dilatation has similar rate 
restenosis like a BMS  
BEST38 
254 pts. 
IVUS guided 
aggressive PCI 
(stent only when 
necessary) vs. 
routine stenting  
16.8%♣ 
aggressive PCI
18.1% stent   
16%♣ – 
aggressive 
PCI  
20% -stent   
IVUS guided aggressive 
PCI with provisional 
stenting is safe and with 
the same results like 
routine stenting  
SIPS39 
269 pts. 
IVUS vs. angio 
guided PCI 
29%♣  IVUS, 
35% angio 
30%∇ IVUS 
37% angio 
same restenosis rate. 
Lower  TLR in IVUS group  
Gaster40 
108 pts. 
IVUS guided vs. 
angio guided (IVUS 
controlled) PCI 
not declared 22%• IVUS 
41% angio 
lower MACE in IVUS 
guided group, better C/E3 
ratio in  IVUS group  
Meuller41  
C/E 
analysis of 
SIPS study 
IVUS guided vs. 
angio guided  PCI 
not declared 19.8%∇ IVUS
31.1% angio 
lower MACE in IVUS 
guided group, better C/E4 
ratio in v IVUS group  
Colombo42* 
130 pts. 
IVUS guided 
intervention in 
lesions longer than 
15 mm 
25%♣ IVUS 
39% angio 
(p< 0.05) 
22%♣ IVUS 
38% angio 
(p< 0.05) 
Lower restenosis, MACE 
and number of stents in 
IVUS group  
+ 12 months MACE, ♣  6 months MACE, • 2,5 year, C/E cost/effectiveness ratio , ∇ 2 years, TLR: target 
lesion revascularization, BMS: bare metal stents  
* non randomized study, control group is composed by similar lesions  
Table 2. IVUS guided coronary intervention  
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The table 3 summarizes the strategy for choosing balloon diameter, acute complications and 
frequency of stenting in aforesaid studies.  
 
study B/A ratio 
 
equation for balloon diameter occurrence of 
acute severe 
dissection  
stenting 
CLOUT34 1.3 * 
0.8-1** 
mean MLDref + mean MVDref / 2 5% not declared 
Haase35  0.8-1 ** EEM in lesion 11% 0% 
Schroeder36 1.4 *  
0.88** 
(2xEEM refprox + 2xEEMrefdist + 
2xEEM lesion)/ 6 
12% 2% 
Abizaid37 1.34 * (EEMmaxlesion + EEM minlesion) / 2 28% 53% 
BEST38 1.25 * (EEM refprox + EEMrefdist) / 2 18% 44% (in IVUS 
group) 
SIPS39 1.23 
IVUS* 
1.03 angio
MLDref + MVDref / 2 (in smallest 
ref. segment) 
 3% IVUS, 
3.2% angio 
49.5% angio, 
49.7% IVUS 
Gaster40 not 
declared 
(MLArefprox + MLArefdist) / 2 not declared  85% angio, 
87% IVUS 
Meuller41 not 
declared 
not declared  not declared  49.5% angio, 
49.7% IVUS 
Colombo42 ° 1.23 ** EEM in lesion 4.6% 51.5% 
Abbreviations: ref – reference segment, refprox  - reference proximal segment, refdist – reference distal 
segment ,   * angiographic, ** IVUS, B/A - balloon artery ratio, mean MLAref – mean lumen in reference 
segments, QCA = quantitative coronary angiography - EEMmaxlesion – maximal EEM in lesions, EEM 
minlesion – minimal EEM in lesions, ° long lesion intervention 
Table 3. Different strategies for choosing of balloon diameter. 
The most frequent formula for choosing of balloon diameter is (EEMrefprox + EEMrefdist ) / 2 
coming form BEST study or just EEMrefdist, which is adapted form the study SIPS. 
IVUS criteria for optimal result after balloon dilatation are listed in table 4. 
 
study criteria
CLOUT34 MLA ≥ 65% mean MLAref, no signs of flow limiting disection  
Haase35 increasing of MLA by at least 20% of EEM,  no signs of flow limiting disection   
Abizaid37 MLA ≥ 65% mean MLAref, or  MLA ≥ 6mm2, no signs of flow limiting disection  
BEST38 residual stenosis < 30% (IVUS and angio), MLA > 6mm2, no signs of flow 
limiting disection    
SIPS39 MLA ≥ 65% mean MLAref, no signs of flow limiting disection  
Mueller41 residual stenosis ≤ 35%, MLA > 65% meanMLAref, no signs of flow limiting 
disection  
Colombo42* MLA ≥ 50% EEMlesion , MLA ≥ 5.5 mm2
Abbreviations: mean MLAref - mean minimal lumen area in reference segment, QCA - quantitative 
coronary angiography, * long lesion intervention  
Table 4. IVUS criteria  of optimal result after balloon dilatation.  
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Based on these studies with IVUS guided balloon dilatation we can summarize: 
1. Using of larger balloons (balloon/artery ratio more than 1 according to angiographic 
assessment) is safe and without increased risk for acute severe complications.  In 
hospital MACE were 1.4-3.9%.  Occurrence of significant dissection varies in large 
range, probably for different definition of this kind of complication. However, all 
authors declare low risk for sever acute dissection.  
2. The rate of in stent restenosis is consistently low in all studies. It means that it is safe to 
avoid stent implantation after fulfilling of IVUS criteria for adequate results after 
balloon dilation. Surprisingly, higher in stent restenosis and higher MACE were found 
in some studies in patients with stent implantation compared to plain balloon 
dilatation. The reason for this finding is probably for bias; according to the study design 
stents were implanted to lesions with non satisfactory results after balloon dilatation or 
for treatment of complications after balloon dilatation. Higher occurrence of in stent 
restenosis and MACE is expected in these types of lesions.  
3. The dark side of IVUS guided balloon angioplasty is a prolonged procedural time (5-13 
minutes), increased X-ray time (2-3.6 minutes) and higher amount of contrast dye (12-34 
ml)38-41 
4. Routine IVUS guided intervention can be beneficial from financial point of view. 
Optimal decision making decreases number of implanted stent and frequency of in 
stent restenosis and avoids peri-procedural complications from non-indicated coronary 
interventions40,41.  
5. IVUS guided intervention should be used for avoiding stent implantation in patients 
unsuitable for dual antiplatelet therapy.  
5. Bare-metal stent implantation  
5.1 Mechanism of lumen enlargement during stent implantation 
The most important mechanisms are plaque redistribution (inside stent) and plaque 
extrusion (outside stent) to the reference segments (more frequently to the distal one)43. 
Plaque redistribution and extrusion play role during restenosis in edge segment of stent44.  
Less important factors are plaque compression, plaque embolization and vessel enlargement 
(more in vessel with negative remodeling before PCI)43.   
Final stent diameter is a result of interplay between pressure during implantation and vessel 
wall resistance. Declared stent diameters for different pressures during dilatation do not 
correlate with real stent diameter after implantation. These numbers for stent diameter come 
from in vitro tests in water and do not reflect real situation in the vessel. Costa et al.45 
compared 200 drug eluting stent diameters from IVUS measurement immediately after 
implantation and declared stent diameter for nominal pressure. At least 90% of minimal 
lumen diameter for nominal pressure was reached only in 4% of stents. In stent area can be 
decreased immediately after implantation also by protrusion of plaque material through the 
struts46 (figure9).  
It is important to distinguish between stent expansion and stent apposition. Expansion 
means ratio between minimal stent area (MSA) and lumen area in reference segment. 
Inadequate expansion (figure 10) can be improved by high pressure postdilatation. 
Apposition reflects contact between stent struts and vessel wall. Inadequate apposition 
(figure 11) can be solved by low pressure dilatation with a bigger balloon.    
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Fig. 9. Plaque protrusion through the struts to the lumen. 
 
 
Fig. 10. Inadequate stent expansion. 
 
 
Fig. 11. Inadequate stent aposition 
5.2 High pressure stent dilatation 
The first implantations of Palmaz-Schatz and Gianturco-Roubin stents were complicated by 
high occurrence of subacute stent thrombosis. Colombo and coworkers started IVUS guided 
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high pressure dilatation, which (together with dual antiagregation) decreased the rate of 
subacute stent thrombosis to 0.9%47.  Routine use of high pressure dilatation (up to 20 atm.) 
improves stent expansion and apposition without increasing acute complications48.  Choi et 
al.49 found, that only 54% of angiographically adequatly expanded stents fulfill IVUS criteria 
for optimal stent expansion. Authors performed high pressure postdilatation and final 
MACE was only 11% in 6 months. This study confirms minimal stent area (MSA) as the 
most important risk factor of restenosis (figure 12). 
 
 
Fig. 12. In stent restenosis 
5.3 IVUS guided stent implantation 
There are many studies focusing on impact of IVUS guidance on stent implantation. They 
are summarized in table 5. 
Different criteria for optimal stent expansion were used in published trials, details are 
summarized in table 6.  
 
study name study goal restenosis  MACE comments 
MUSIC50 
161 pts. 
restenosis during 
IVUS guided stent 
implantation 
9.7% 12.1% + the second lowest 
restenosis rate in studies 
with BMS  
Blasini51 
105 pts. 
IVUS vs. angio* 
guided stent 
implantation 
20.9% IVUS 
29.9% angio 
(p=0.033) ** 
not analyzed Restenosis 13.5% in stent 
fulfilling IVUS criteria 
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study name study goal restenosis  MACE comments 
RESIST52 
study 
155 pts. 
IVUS vs. angio 
guided (IVUS 
controlled) stent 
implantation 
22.5% IVUS 
28.8% angio 
(p=0.25) 
not declared IVUS guidance does not 
decrease rate of in stent 
restenosis 
OPTICUS53 
550 pts. 
IVUS vs. angio 
guided stent 
implantation  
24.5% IVUS 
22.5% angio  
(p=0.68) 
17.9%♣ IVUS
15.3% angio 
(p=0.4) 
IVUS guiding do not 
decrease neither rate of in 
stent restenosis nor 
MACE  
CRUISE54 
499 pts. 
IVUS vs. angio 
guided (IVUS 
controlled) stent 
implantation 
not declared TVR 
8.5%• in 
IVUS group 
15.3% in 
angio group 
(p=0.019) 
IVUS guided stenting 
leads to lower TVR 
Choi49 
278 pts. 
IVUS vs. angio 
guided stent 
implantation 
not declared  12%+IVUS 
19% angio 
(p=0,11) 
 
IVUS leads to lower 
periprocedural 
complications with a 
trend for lower TVR in 
IVUS group(p=0.08) 
AVID55 
800 pts. 
IVUS vs. angio 
guided stent 
implantation 
not declared 18%  IVUS 
19% angio 
IVUS leads to larger 
lumen, but without any 
effect on 30 days and 12 
months MACE 
TULIP56 
150 pts. 
IVUS vs. angio 
guided stenting of 
long lesions 
23%+ IVUS 
46% angio 
(p=0.008)  
6%+ IVUS 
20% angio 
(p=0.01) 
Better clinical and 
angiographic results in 
IVUS group despite more 
implanted stents  
PRESTO57       
796 pts with 
IVUS vs. 
8274 with 
angio 
IVUS vs. angio 
guided stenting  
not declared  TVR 13.8% 
IVUS 12.2% 
angio (p=0.9)
Larger MLD in IVUS 
group, but without 
difference in MACE. 
Criteria for adequate 
IVUS stent expansion 
was let only on operators 
discretion  
DIPOL58 163 
pts. 
IVUS vs. angio 
guided stenting 
10% IVUS 27% 
angio 
7.3% IVUS 
16% angio 
Best results for IVUS 
guided in randomized 
trial 
Gaster55,60 
108 pts 
IVUS vs. angio 
guided stenting 
16% IVUS 
25% angio 
22% IVUS 
41% angio 
IVUS guiding is cost 
saving 
* non randomized trial, angio group is a historic control, ** IVUS criteria was fulfilled in 49.5% patients 
and in these ones was restenosis 13.5%, + 6 months, ♣ 12 months, • 9 months, TVR - target vessel 
revascularization 
Table 5. Trials assessing IVUS guided stent implantation.  
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study  criteria for optimal expanded stent  
Katritsis61 full stent apposition, MSA ≥ 90% meanMLAref, symmetrical expansion (min 
SD/maxSD > 0.7) (correlation with FFR 0.94) 
Fearon62 MSA 7 mm2 (correlates with FFR 0.96) 
Hanekamp63 full stent apposition, MSA ≥ 90% meanMLAref, or MSA ≥ 100% minMLAref, 
symetrical expansion (minSD/maxSD > 0.7), (correlation with FFR 0.94) 
Gorge48 symmetrical stent expansion, MSD ≥ 3 mm, full apposition  
Choi49  complete stent apposition, MSA ≥ 80% distalMLAref , symmetrical expansion 
(minSD/maxSD > 0.8)  
Colombo47 full stent apposition , MSA ≥  minMLAref, MLA >  60% MLAref in edge regions 
Ahmed44 complete stent apposition, MSA ≥ 80% meanMLAref or MSA 7.5 mm2 
MUSIC50* 
 
- complete stent apposition, MSA ≥ 90 meanMLAref  or ≥ 100 minMLAref   
- in case of > 9 mm2 : 
MSA ≥ 80% meanMLAref  or ≥ 90% minMLAref   
MSA in proximal part of stent ≥ 90% proxMLAref 
symmetrical expansion (minSD/maxSD > 0.7) 
Blasini51 full stent apposition, MSA > 8 mm2, or MSA ≥ 90% meanMLAref, complete 
coverage of dissection 
RESIST52 MSA ≥ 80% meanMLAref   
OPTICUS53 MUSIC criteria, residual stenosis les than  10% (angiographically) 
CRUISE54 residual stenosis < 10% (angiographically)  
AVID55 full stent apposition, residual stenosis < 10%, no signs of dissection 
TULIP56 complete stent apposition, MSD ≥ 80% meanMLDref , MSA ≥ 90% distalMLAref   
Abbreviations: SD - stent diameter, meanMLAref  -  mean minimal lumen area in reference segments, 
minMLAref minimal - minimal lumen area i reference segments, MSD – minimal stent diameter, MSA – 
minimal stent area   
* all criteria were fulfilled in 81% patients and these patients were treated only with acetylosalycilic acid 
and rate of subacute  stent thrombosis was 1.3%  
Table 6. Different criteria for optimal stent expansion.  
The main goal for IVUS guidance of stent implantation is a larger minimal stent diameter and 
minimal stent area. Further improvement is seen in strut apposition.  Minimal stent area is the 
most important risk factor for development of in stent restenosis (ISR). The cut-off point for 
risk of ISR is 8mm2 in vessel ≥ 3 mm and 6  mm2 in vessel < 3mm64. The rate of in stent 
restenosis according to achievement of different IVUS parameters is summarized in table 7.  
 
criteria restenosis rate 
MSA > 9 mm2 11%
MSA > 9 mm2 a MSA ≥ 80% meanMLAref 12.5%
MSA ≥ 55% meanEEMref 17%
MSA ≥ 90% meanMLAref 21%
MSA ≥ 90% distal MLAref 22%
Abbrevation: MSA – minimal stent area 
Table 7. Risk of ISR and achievement of different IVUS parameters. 
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The lowest rate of ISR is in stents with MSA > 9mm2. However, for achievement of this MSA 
it is necessary to use a 3.5mm stent (with ideal stent area 9.6mm2), because 3mm stent has an 
ideal stent area 7.1mm2. MSA 8 mm2 as a sufficient post-stenting area was confirmed by 
Hoffmann et al65. They found a mean MSA in stent with ISR 7.1mm2 and 8.1mm2 in stents 
without development of ISR. This cut-off MSA is also a predictor for development of ISR in 
long stents66. Further predictors for ISR are: 
- length of stents67  
- strong calcification68  
- bulky plaque compensated by positive vessel remodelation69-72 (figure 13)   
- plaque protrusion through the stent struts73  
MSA is the most important factor for development of in stent thrombosis (IST)74. The 
incidence of this feared complication is less than 0.5%74. 
Parise et al.75 published recently a meta-analysis of all randomized studies comparing IVUS 
guided vs. angio guided stenting in pre-drug-eluting stent era. They concluded that IVUS 
guided stenting significantly lowered the 6-month angiographic restenosis rates, 12-month 
revascularization and MACE rate. They did not find any effect of IVUS guidance on death 
or myocardial infarction.  
 
 
Fig. 13. Large plaque compensated by positive vessel remodeling 
6. Drug-eluting stent implantation 
Drug eluting stents (DES) significantly reduce the risk of in stent restenosis compared to 
BMS76-78. IVUS guidance   seemed to be needless for DES excellent results. However, several 
issues are still a problem even with the use of DES and some of them, like in stent 
thrombosis, seem to be more important than in BMS .  
In stent restenosis still exists and it´s incidence is 5-10%  in selected populations79-80. It seems to 
be more pronounced in paclitaxel eluting stent than sirolimus eluting stents81. Minimum stent 
area that best separates restenosis from no restenosis in DES is between 5.0-6.0 mm2 82,83. 
The occurrence of in stent thrombosis (IST) in DES is 1-1.5%84. The main cause of IST is stent 
under expansion. DES with further IST development showed significantly lower MSA (4.3-
4.6 mm2). Further risk factor for IST development is residual edge stenosis, defined as a 
MLA < 4 mm2 and a plaque burden > 70%85,74. These risk factors remain the same like in 
BMS, where the presence of dissection, thrombus or tissue prolaps into the stent were 
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recognized as further risk factors for IST development86,87. The occurrence of IST in BMS is 
estimated  at 0.9%88.  
The risk factors for IST development can be revealed by IVUS control after stent 
implantation. Roy et al.89 published study, where IVUS guidance of DES implantation 
reduced development of IST in 30 days (0.5% in IVUS vs. 1.5% in angio guided group)  and 
12 month (0.7% in IVUS vs. 2.0% in angio guided group), as well as decreased need for 
revascularization and MACE in 30 day. Unfortunately, there were no clear criteria for 
adequate stent deployment in this study. Claessen et al.90 published a study comparing 
angio and IVUS guidance in 1504 sirolimus eluting stent implantation in the MATRIX 
(Comprehensive Assessment of Sirolimus-Eluting Stents in Complex Lesions) registry. They 
found significantly lower occurrence of myocardial infarction and combined endpoint of 
myocardial infarction and death in IVUS guided group. Hur et al.91 published their 
enormous registry  of angio (3744 patients) versus IVUS (4627 patients) guided stent 
implantation. The main finding of this study is lower mortality in IVUS guided group. This 
result was seen mainly in DES implantation, because mortality in BMS group was the same. 
However, the explanation of this interesting finding is not clear, because the occurrence of 
myocardial infarction, target vessel revascularization and in stent thrombosis was without 
significance differences between angio and IVUS group. Based on aforesaid trials we can 
conclude, that IVUS guidance of DES implantation probably improves patient’s outcome, 
but further trials are needed for better understanding of this phenomenon.  
Important phenomenon in DES implantation is incomplete stent apposition (ISA), which 
means, that at least one strut is not adequately apposed to vessel wall. One should 
distinguish between acute stent malapposition, which is present immediately after stent 
implantation, late  stent malapposition (LSM), which can be persistent , it means that acute 
malapposition is not healed and late-acquired stent malapposition (LASM), which develops 
despite normal finding after stent implantation. The mechanism of LASM development is 
not known, several mechanisms are thought: 
- positive vessel remodeling leading to vessel enlargement   
- decrease of plaque volume behind the stent caused by antiproliferative effect of DES 
- thrombus dissolution after PCI of thrombus containing lesions 
The frequency of LSM is not clear, a quite broad range for this phenomenon was published 
(4-21%)92,93. LSM is not found only in DES, but also in BMS, where it’s incidence is 4.4-
5.4%94,95. Empty space behind stent struts can lead to decrease of blood flow in this region 
and cause development of thrombosis. However, this theoretic concept was not proved in 
any study following the natural course of patients with LSM. Hong et al.96,97 did not find any 
clinical adverse event in patient with LSM during 10 months follow up. On the other hand 
Cook et al.98 published correlation between LSM and very late IST. Moreover, Hassan et al.99 
published meta-analysis of 17 randomized trials focusing on LSM in BMS as well as DES. 
They found four times higher risk of LASM in patients with DES compared to BMS and 
LSM (acquired or persistent) increased significantly risk for (very) late in stent thrombosis 
(OR 6,51).     
A rare complication (1.25%) of DES implantation is development of coronary aneurysm. The 
definition of aneurysm is focal enlargement of vessel lumen, which is 50% larger than 
adjacent reference vessel.  Coronary aneurysm is not a benign finding as up to 40% of 
patients needed revascularization in a study done by Alfonso et al.100.   
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7. Ivus guided pci in specific situation 
7.1 PCI of bifurcation lesions 
PCI in bifurcation is a more challenging procedure with a risk of compromising flow in side 
branch (SB) and with higher rate of restenosis. The “classical“ mechanisms of worsening 
flow in side branch were thought 101  
- plaque compression in ostial part of  SB during dilatation in main vessel (MV). The 
presence of diffuse ostial plaque (figure 14) has higher risk for TIMI 2 flow after stenting 
than presence of eccentric plaque102  
- plaque shifting from the MV to SB during dilatation in MV (“snow-plow” 
phenomenon)  
- interposition of stent struts across the ostium of  SB 
 
 
Fig. 14. Bifurcation with diffuse impairment of side branch ostium. 
Plaque in bifurcation  is mainly localized in counter carina103. However, Medina et al.104 
proved the presence of plaque also in carina. They found plaque  in 32% of bifurcations and 
moreover, in 16% of bifurcations the plaque in the carina was larger than in counter carina 
area. Furthermore, authors showed, that the mechanism of ostial SB damage after stent 
implantation in the MV was always due to displacement of the carina and no cases of 
plaque shifting were found. Further interesting finding of this study is that plaque in the 
carina was greater in the bifurcations that had maximum stenosis located distal to the carina 
in the MV. Authors explain this finding by hypothesis of different flow velocity patterns in 
these lesions. Atheroprotective high shear stress can be transformed into an atero-prone low 
shear stress. Authors describe less damage of SB ostium after stenting of lesions with plaque 
at the carina. Plaque probably makes carina more resistant and does not allow carina 
shifting, which is now thought to be a dominant mechanism causing damage to the SB 
ostium when a stent is implanted into the MV. 
Important contribution for planning of PCI in bifurcations is a study done by Costa et al105. 
They found that the part of MV just behind the origin of SB (so called “lower diamond” or 
“polygon of confluence”) is more prone for small minimal stent area after dilatation of SB 
ostium, which is not reverted even after kissing balloon dilatation. Kang et al.106 published a 
study assessing the IVUS predictors for side branch compromise after single-stent crossover 
technique and found two predictors for post stenting FFR<0.8: MLA 2.4mm2 and PB > 51%  
in SB ostium.  
www.intechopen.com
 IVUS Guided PCI 
 
125 
Main role of IVUS guidance in bifurcation PCI is precise assessment of atherosclerotic 
burden of main vessel, carina, ostial part of side branch and the choice of the best strategy 
based on these findings. IVUS can improve the choice of ideal stent diameter, because 
bifurcation area is frequently affected by negative remodeling, which is not visible in 
routine angiography107.  
IVUS should be used of most cases of uncertain atherosclerotic distribution in bifurcation 
lesions, because in case of favorable finding in SB ostium a planned complex procedure can 
be converted to a simple one with just stenting of MV.  
7.2 PCI of chronic total occlusion 
The main disadvantage for IVUS guidance of chronic total occlusion (CTO) interventions is 
the lateral view of IVUS probe. A prototype of forward-looking IVUS system was 
developed, but till now it has never been commercialized. IVUS can help during wire 
introduction  to the proximal fibrous cap of CTO in presence of side branch just proximal to 
occluded segment. IVUS is introduced to this side branch and from this location  the wire 
reaching the origin of total occlusion can be visualized (figure 15). IVUS also can help with 
re-introduction  of wire from false lumen to the true lumen, but it is necessary to introduce 
the IVUS probe to the false lumen after its predilatation with small balloon108.  This 
technique unfortunately increases risk of vessel perforation.  
 
 
Fig. 15. Schema of IVUS guidance during PCI of chronic total occlusion. 
8. Complications 
8.1 Dissections 
Dissections are tears in the plaque that are parallel to the vessel wall with blood flow in the 
false lumen and tend to occur at the junction of elements with different compliance (plaque 
and normal vessel wall, edges of stents) (figure 16, 17). Dissections can be described as 
proximal or distal to the lesion; epicardial or myocardial; and according to length, 
circumferential arc, depth, lumen compromise, bulkiness and mobility of the flap5.  The major 
predictor of an unfavorable prognosis of dissection is a decreased blood flow in affected 
coronary artery. This situation must be solved immediately. IVUS can also detect dissections, 
which are not visible on angiography and it is questionable how many of them should be 
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treated. Nishida et al.109 followed 124 patients with non-flow limiting dissection (65% of them 
were after stenting). They found that dissection can be let untreated if the residual lumen is 
more than 6 mm2 and lumen area is more than 40% of the EEM area. The edge dissections after 
stenting, which can be visualized only by IVUS and are not apparent during angiography, are 
not indicated for any intervention, because of good prognosis by spontaneous healing110.   
 
 
Fig. 16. Dissection with tear reaching  to the media. 
 
 
Fig. 17. Complex dissection with IVUS probe in true lumen, one false lumen is located down 
to true lumen (♣) and another entry to the false lumen is located above the true lumen (∗). 
8.2 Intramural hematomas 
Intramural hematoma is a variant of a dissection. The angiographic appearance ranges from 
a dissection, thrombus, and abrupt closure to non-significant abnormality. The EEM 
expands outwards and the intima is pushed inwards and straightens to cause lumen 
compromise (figure 18). Blood accumulates in the space caused by the split in the media and 
becomes static and echogenic. The hematoma can propagate antegrade or retrograde, but 
tends to be stopped by branches or severely diseased parts of the vessel (particularly 
calcified plaques). In a study, which included more than 1000 patients with IVUS control 
after PCI, an intramural hematoma was found in 6.7 % with a high rate of clinical events5, 111. 
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Fig. 18. Intramural haematoma. Bleeding to the media and adventicia is compromising 
lumen.  
8.3 Haziness 
IVUS is a very useful tool for diagnosis of underlying processes causing a hazy appearance 
of lesions after PCI. The most common findings are large residual plaque burden, dissection 
and plaque protrusion. Rarely stent deformation or intramural hematoma can be found. 
Intimal wrinkling can occur when a vessel is straightened by a guidewire. It reverses when 
the wire is removed or when the stiff wire is exchanged for a soft one. A narrowing of the 
lumen with a  straightening of a normal-looking intima,  behind which is an echolucent zone 
can be seen in IVUS picture. Discontinuity of the EEM can be found, which is caused by 
simultaneously visualized both sides of fold in the artery. Finally, it is important to 
recognize an angiographic pseudo complication with normal IVUS finding5.   
9. Conclusions 
Based on studies focusing on IVUS guidance of stent implantation we can summarize: 
1. Based on  IVUS criteria we can probably safely defer PCI  
2. Satisfactory IVUS finding after balloon dilatation has same results as a stenting with BMS  
3. IVUS guidance decreases angiographic restenosis and consequently the revascularization 
 and MACE rate 
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4. IVUS guidance decreases rate of in stent thrombosis 
5. Contraindication for IVUS guidance are small vessels, tortuous vessels and degenerated 
 vein grafts 
This summary raises the question why IVUS is not used routinely during all PCI 
procedures. The answers can be divided into two groups. First there are the lessons we have 
learned from IVUS and this phenomenon is known as an “IVUS eye”. We know that vessels 
are bigger than they look on angio and we are using bigger stents than before IVUS studies. 
We know, that without high pressure post dilatation we are not able to achieve sufficient 
stent diameter despite information derived from manufacturer’s compliance charts. These 
factors dramatically contributed to lowering of in stent restenosis and therefore it is difficult 
to find statistical significant difference between IVUS and angio guided interventions, like it 
was described in OPTICUS  trial. However, IVUS is still irreplaceable during investigation 
of unclear finding during angiography (like hazy lesions) or after stenting. IVUS is 
especially recommended during PCI of left main, the last remaining coronary artery and PCI 
in patients who are contraindicated for dual antiplatelet therapy for avoiding stent 
implantation. Furthermore, precise assessment of bifurcation can change the strategy from 
more complex to simple one in case of low risk profile of ostial part of side branch 
The group of arguments against routine use of IVUS during PCI is cost of IVUS catheter, 
longer procedural time and higher contrast dye consumption.  Moreover IVUS guided PCI 
are more complex and need more skills than angio guided ones. However, in indicated cases 
IVUS guidance  undoubtedly improves short as well as long term of coronary interventions.     
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